<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2025-4522</article-id><article-id custom-type="edn" pub-id-type="custom">NZVYAU</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-4522</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КАРДИОМИОПАТИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CARDIOMYOPATHY</subject></subj-group></article-categories><title-group><article-title>Ранняя фибрилляция предсердий у пациентов с кардиомиопатией: клинико-генетическая структура и влияние на прогноз</article-title><trans-title-group xml:lang="en"><trans-title>Early­onset atrial fibrillation in patients with cardiomyopathy: clinical and genetic structure and impact on prognosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2127-8525</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вайханская</surname><given-names>Т. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Vaykhanskaya</surname><given-names>T. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Геннадьевна Вайханская — к.м.н., в.н.с. лаборатории медицинских информационных технологий </p><p>220036, ул. Розы Люксембург, д. 110Б, Минск</p></bio><bio xml:lang="en"><p>Rosa Luxemburg St., 110B, Minsk, 220036</p></bio><email xlink:type="simple">tat_vaikh@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8155-4384</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Геворкян</surname><given-names>Т. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Gevorkyan</surname><given-names>T. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Тельмановна Геворкян — врач отделения функциональной диагностики</p><p>220036, ул. Розы Люксембург, д. 110Б, Минск</p></bio><bio xml:lang="en"><p>Rosa Luxemburg St., 110B, Minsk, 220036</p></bio><email xlink:type="simple">gtt74@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3325-0917</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левданский</surname><given-names>О. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Levdansky</surname><given-names>O. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Олег Дмитриевич Левданский — к.б.н., зав. сектором биоинформатики</p><p>ул. Академическая, д. 27, Минск</p></bio><bio xml:lang="en"><p>Akademicheskaya St., 27, Minsk</p></bio><email xlink:type="simple">o.liaudanski@igc.by</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7503-9936</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коптюх</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Koptyukh</surname><given-names>T. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Михайловна Коптюх — врач кабинета программации имплантированных электронных устройств</p><p>220036, ул. Розы Люксембург, д. 110Б, Минск</p></bio><bio xml:lang="en"><p>Rosa Luxemburg St., 110B, Minsk, 220036</p></bio><email xlink:type="simple">tat_koptuh@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГУ Республиканский научно-практический центр "Кардиология"<country>Беларусь</country></aff><aff xml:lang="en">Republican Scientific and Practical Center of Cardiology<country>Belarus</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ГНУ Институт генетики и цитологии Национальной Академии наук Беларуси<country>Беларусь</country></aff><aff xml:lang="en">Institute of Genetics and Cytology<country>Belarus</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>11</day><month>11</month><year>2025</year></pub-date><volume>24</volume><issue>9</issue><fpage>4522</fpage><lpage>4522</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Вайханская Т.Г., Геворкян Т.Т., Левданский О.Д., Коптюх Т.М., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Вайханская Т.Г., Геворкян Т.Т., Левданский О.Д., Коптюх Т.М.</copyright-holder><copyright-holder xml:lang="en">Vaykhanskaya T.G., Gevorkyan T.T., Levdansky O.D., Koptyukh T.M.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/4522">https://cardiovascular.elpub.ru/jour/article/view/4522</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучение генотип-фенотипического спектра кардиомиопатии (КМП) с фибрилляцией предсердий (ФП), оценка клинических исходов и прогностической значимости генотипирования ранней манифестации ФП у пациентов с дилатационной КМП (ДКМП) и недилатационной КМП (НДКМП) левого желудочка (ЛЖ).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включили 220 генотипированных пациентов с КМП: 186 лиц с ДКМП — 127 (68,3%) мужчин, возраст 44 [34; 55] лет, фракция выброса (ФВ) ЛЖ 30 [25; 36]% и 34 пациента с НДКМП ЛЖ — 23 (67,6%) мужчин, возраст 35 [32; 41] лет, ФВ ЛЖ 53 [47; 60]%. Период наблюдения составил 7 лет (Ме 85 [69; 202] мес.). В когортах сравнили частоту развития ранней ФП (в возрасте &lt;45 лет), генетический спектр КМП и клинические исходы.</p></sec><sec><title>Результаты</title><p>Результаты. Ранняя ФП (пароксизмальная, персистирующая или постоянная) зарегистрирована у 48 пациентов в возрасте 35,3±6,8 лет, "поздняя" ФП наблюдалась у 33 лиц в возрасте 53,2±3,7 лет. Патогенные варианты в генах LMNA, TTN и SCN5A, выявленные у 19 (54,3%) пациентов, составили более половины всех генотипов с ранним дебютом ФП. В когорте ламинопатий (n=19) частота фенотипа с ранней ФП была самой высокой и составила 52,6%. Среди всех пациентов с ранним началом ФП распространенность LMNA мутаций составила 20,8%; варианты TTN с потерей функции были обнаружены у 12,5%. Вероятность обнаружения варианта, ассоциированного с КМП, была наиболее высокой (отношение шансов (OR — odds ratio) 17,4; 95% доверительный интервал (ДИ): 4,49-69,1) у лиц с ранней ФП, диагностированной в возрасте &lt;34 лет при наличии семейного анамнеза КМП, а наиболее низкой — в возрасте &gt;50 лет (χ2=30,2; р&lt;0,001). В результате многофакторного Кокс-регрессионного анализа, ранняя ФП с патогенным генотипом КМП определена в качестве независимого предиктора смерти от всех кардиоваскулярных причин (отношение рисков (HR — hazard ratio) 2,11; 95% ДИ: 1,09-4,07; p=0,027).</p></sec><sec><title>Заключение</title><p>Заключение. Варианты в генах LMNA, TTN и SCN5A доминируют у пациентов с генетической КМП и ранней ФП. Обнаружены значимые ассоциации между генотип-позитивной КМП с ранним началом ФП и неблагоприятными клиническими исходами.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the genotype and phenotype cardiomyopathy profile with atrial fibrillation (AF), as well as to evaluate the clinical outcomes and prognostic significance of genotyping early manifestations of AF in patients with dilated cardiomyopathy (DCM) and non-dilated left ventricular cardiomyopathy (NDLVC).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 220 genotyped patients with cardiomyopathy as follows: 186 patients with DCM — 127 (68,3%) men, aged 44 [34; 55] years, left ventricular ejection fraction (LVEF) 30 [25; 36]%; 34 patients with NDLVC — 23 (67,6%) men, aged 35 [32; 41] years, LVEF 53 [47; 60]%. The follow-up period was 7 years with Me of 85 [69; 202] months. The cohorts were compared for the incidence of early-onset AF (at age &lt;45 years), the genetic profile of cardiomyopathy, and clinical outcomes.</p></sec><sec><title>Results</title><p>Results. Early-onset AF (paroxysmal, persistent, or permanent) was registered in 48 patients aged 35,3±6,8 years, while late-onset AF — in 33 individuals aged 53,2±3,7 years. Pathogenic variants in the LMNA, TTN, and SCN5A genes, identified in 19 (54,3%) patients, accounted for more than half of all genotypes with early-onset AF. In the laminopathy cohort (n=19), the prevalence of early-onset AF phenotype was the highest and amounted to 52,6%. Among all patients with early-onset AF, the prevalence of LMNA mutations was 20,8%; loss-of-function TTN variants were detected in 12,5%. The probability of detecting a cardiomyopathy-related variant was highest (odds ratio (OR) 17,4; 95% confidence interval (CI): 4,49-69,1) in individuals with early AF diagnosed at the age of &lt;34 years with a family history of cardiomyopathy, and lowest in those &gt;50 years old (χ2=30,2; p&lt;0,001). Multivariate Cox regression analysis revealed that early AF with the pathogenic cardiomyopathy genotype was an independent predictor of cardiovascular death (hazard ratio (HR) 2,11; 95% CI: 1,09-4,07; p=0,027).</p></sec><sec><title>Conclusion</title><p>Conclusion. Variants in the LMNA, TTN, and SCN5A genes predominate in patients with genetic cardiomyopathy and early AF. Significant associations were found between genotype-positive cardiomyopathy with early-onset AF and unfavorable outcomes.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ранняя фибрилляция предсердий</kwd><kwd>дилатационная кардиомиопатия</kwd><kwd>генотип</kwd><kwd>ген LMNA</kwd><kwd>прогноз</kwd><kwd>отношение рисков</kwd><kwd>кардиоваскулярная смертность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>early atrial fibrillation</kwd><kwd>dilated cardiomyopathy</kwd><kwd>genotype</kwd><kwd>LMNA gene</kwd><kwd>prognosis</kwd><kwd>hazard ratio</kwd><kwd>cardiovascular mortality</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Литература/References</mixed-citation><mixed-citation xml:lang="en">Laws JL, Shabani M, Williams HL, et al. The Therapeutic Impact of Genetic Evaluation in an Atrial Fibrillation Precision Medicine Clinic. medRxiv [Preprint]. 2025:2025.03.28.25324544. doi:10.11 01/2025.03.28.25324544.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Laws JL, Shabani M, Williams HL, et al. The Therapeutic Impact of Genetic Evaluation in an Atrial Fibrillation Precision Medicine Clinic. medRxiv [Preprint]. 2025 Mar 30:2025.03.28.25324544. doi: 10.1101/2025.03.28.25324544.</mixed-citation><mixed-citation xml:lang="en">Yoneda ZT, Anderson KC, Quintana JA, et al. Early­Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiol. 202;6(12):1371­9. doi:10.1001/jamacardio.2021.3370.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yoneda ZT, Anderson KC, Quintana JA, et al. Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiol. 202;6(12):1371–1379. doi: 10.1001/jamacardio.2021.3370.</mixed-citation><mixed-citation xml:lang="en">Yeung C, Enriquez A, Suarez­Fuster L, et al. Atrial fibrillation in patients with inherited cardiomyopathies. Europace. 2019;21:22­ 32. doi:10.1093/europace/euy064.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Yeung C, Enriquez A, Suarez-Fuster L, et al. Atrial fibrillation in patients with inherited cardiomyopathies. Europace. 2019;21:22–32. doi: 10.1093/europace/euy064.</mixed-citation><mixed-citation xml:lang="en">Yoneda ZT, Anderson KC, Fei Y, et al. Mortality in early­onset atrial fibrillation and rare variants in cardiomyopathy and arrhythmia genes. JAMA Cardiol. 2022;7(7):733­41. doi:10.1001/jamacardio. 2022.0810.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Yoneda ZT, Anderson KC, Fei Y, et al. Mortality in early-onset atrial fibrillation and rare variants in cardiomyopathy and arrhythmia genes. JAMA Cardiol. 2022;7(7):733–741. doi: 10.1001/jamacardio.2022.0810.</mixed-citation><mixed-citation xml:lang="en">Charron P, Elliott PM, Gimeno JR, et al. The Cardiomyopathy Registry of the EURObservational Research Programme of the ESC. Eur Heart J. 2018;39:1784­93. doi:10.1093/eurheartj/ehx819.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Charron P, Elliott PM, Gimeno JR, et al. The Cardiomyopathy Registry of the EURObservational Research Programme of the ESC. Eur Heart J. 2018; 39: 1784–1793. doi: 10.1093/eurheartj/ehx819.</mixed-citation><mixed-citation xml:lang="en">Buckley BJR, Harrison SL, Gupta D, et al. Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real­World Data. J Am Heart Assoc. 2021;10(23):e021970. doi:10.1161/jaha.121.021970.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Buckley BJR, Harrison SL, Gupta D, et al. Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real-World Data. J Am Heart Assoc. 2021;10(23):e021970. doi:10.1161/jaha.121.021970.</mixed-citation><mixed-citation xml:lang="en">Verdonschot JAJ, Hazebroek MR, Krapels IPC, et al. Implications of genetic testing in dilated cardiomyopathy. Circ Genom Precis Med. 2020;13:476­87. doi:10.1161/CIRCGEN.120.003031.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Verdonschot JAJ, Hazebroek MR, Krapels IPC, et al. Implications of genetic testing in dilated cardiomyopathy. Circ Genom Precis Med. 2020;13:476–487. doi: 10.1161/CIRCGEN.120.003031.</mixed-citation><mixed-citation xml:lang="en">Gigli M, Merlo M, Graw SL, et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2019;74:1480­90. doi:10.1016/j.jacc.2019.06.072.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gigli M, Merlo M, Graw SL, et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2019; 74:1480–1490. doi: 10.1016/j.jacc.2019.06.072.</mixed-citation><mixed-citation xml:lang="en">Li Z, Chen P, Li C, et al. Genetic arrhythmias complicating patients with dilated cardiomyopathy. Heart Rhythm. 2020;17(2):305­12. doi:10.1016/j.hrthm.2019.09.012.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Li Z, Chen P, Li C, et al. Genetic arrhythmias complicating patients with dilated cardiomyopathy. Heart Rhythm. 2020;17(2):305–312. doi: 10.1016/j.hrthm.2019.09.012.</mixed-citation><mixed-citation xml:lang="en">Towbin JA. Genetic arrhythmias complicating patients with dilated cardiomyopathy: How it happens. Heart Rhythm. 2020;17(2):31314. doi:10.1016/j.hrthm.2019.10.019.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Towbin JA. Genetic arrhythmias complicating patients with dilated cardiomyopathy: How it happens. Heart Rhythm. 2020;17(2):313–314. doi: 10.1016/j.hrthm.2019.10.019.</mixed-citation><mixed-citation xml:lang="en">Barrett KMS, Cirulli ET, Bolze A, et al. Cardiomyopathy prevalence exceeds 30% in individuals with TTN variants and early atrial fibrillation. Genet Med. 2023;25(4):100012. doi:10.1016/j.gim. 2023.100012.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Barrett KMS, Cirulli ET, Bolze A, et al. Cardiomyopathy prevalence exceeds 30% in individuals with TTN variants and early atrial fibrillation. Genetics in Medicine. 2023; 25(4):100012. doi: 10.1016/j.gim.2023.100012.</mixed-citation><mixed-citation xml:lang="en">Arbelo E, Protonotarios A, Gimeno JR, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503­626. doi:10.1093/eurheartj/ehad194.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Arbelo E, Protonotarios A, Gimeno JR, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–3626. doi: 10.1093/eurheartj/ehad194.</mixed-citation><mixed-citation xml:lang="en">Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405­24. doi:10.1038/gim.2015.30.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17:405–424. doi: 10.1038/gim.2015.30.</mixed-citation><mixed-citation xml:lang="en">Van Gelder IC, Rienstra M, Bunting KV, et al. ESC Scientific Document Group, 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio­Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2024;45(36):3314­414. doi:10.1093/eurheartj/ehae176.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Van Gelder IC, Rienstra M, Bunting KV, et al. ESC Scientific Document Group, 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). European Heart Journal. 2024; 45(36):3314–3414. doi:10.1093/eurheartj/ehae176.</mixed-citation><mixed-citation xml:lang="en">Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.) doi:10.15829/1560­4071­2024­6162.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Loukianov MM, Martsevich SY, Mareev YV, et al. Patients with a Combination of Atrial Fibrillation and Chronic Heart Failure in Clinical Practice: Comorbidities, Drug Treatment and Outcomes. Rational Pharmacotherapy in Cardiology. 2021;17(6):816-24. (In Russ.) Лукьянов М.М., Марцевич С.Ю., Мареев Ю.В. и др. Больные с сочетанием фибрилляции предсердий и хронической сердечной недостаточности в клинической практике: сопутствующие заболевания, медикаментозное лечение и исходы. Рациональная Фармакотерапия в Кардиологии. 2021;17(6):816824. doi:10.20996/1819-6446-2021-12-05.</mixed-citation><mixed-citation xml:lang="en">Loukianov MM, Martsevich SY, Mareev YV, et al. Patients with a Combination of Atrial Fibrillation and Chronic Heart Failure in Clinical Practice: Comorbidities, Drug Treatment and Outcomes. Rational Pharmacotherapy in Cardiology. 2021;17(6):816­24. (In Russ.) doi:10.20996/1819­6446­2021­12­05.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Martsevich SY, Kutishenko NP, Lukina Y V, et al. Observational studies and registers. Their quality and role in modern evidence-based medicine. Cardiovasc Ther Prev. 2021;20(2):61-6 (In Russ.) Марцевич С.Ю., Кутишенко Н.П., Лукина Ю.В., и др. Наблюдательные исследования и регистры. Их качество и роль в современной доказательной медицине. Кардиоваскулярная терапия и профилактика. 2021;20(2):2786. doi:10.15829/1728-8800-2021-2786.</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Kutishenko NP, Lukina YV, et al. Observational studies and registers. Their quality and role in modern evidencebased medicine. Cardiovascular Therapy and Prevtntion. 2021;20(2):2786. (In Russ.) doi:10.15829/1728­8800­2021­2786.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Polyakov DS, Fomin IV, Valikulova FY, et al. The EPOCH-CHF epidemiological program: decompensated chronic heart failure in real-life clinical practice (EPOCH-D-CHF). Russ Hear Fail J. 2016;17(6):299-305 (In Russ.) Поляков Д.С., Фомин И.В., Валикулова Ф.Ю., и др. Эпидемиологическая программа ЭПОХА-ХСН: декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА-Д-ХСН). Сердечная Недостаточность. 2016;17(5):299–305. doi:10.18087/RHFJ.2016.5.2239.</mixed-citation><mixed-citation xml:lang="en">Polyakov DS, Fomin IV, Valikulova FY, et al. The EPOCH­CHF epidemiological program: decompensated chronic heart failure in real­life clinical practice (EPOCH­D­CHF). Russ Hear Fail J. 2016;17(5):299­305. (In Russ.) doi:10.18087/RHFJ.2016.5.2239.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Antonopoulos AS, Kasiakogias A, Kouroutzoglou A, et al. Atrial fibrillation burden and management in cardiomyopathies: Current evidence and unmet needs. Trends Cardiovasc Med. 2025;35(5):284–293. doi: 10.1016/j.tcm.2025.01.007.</mixed-citation><mixed-citation xml:lang="en">Antonopoulos AS, Kasiakogias A, Kouroutzoglou A, et al. Atrial fibrillation burden and management in cardiomyopathies: Current evidence and unmet needs. Trends Cardiovasc Med. 2025;35(5): 284­93. doi:10.1016/j.tcm.2025.01.007.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tremblay-Gravel M, Ichimura K, Picard K, et al. Intrinsic Atrial Myopathy Precedes Left Ventricular Dysfunction and Predicts Atrial Fibrillation in Lamin A/C Cardiomyopathy. Circ Genom Precis Med. 2023;16(1):e003480. doi: 10.1161/CIRCGEN.121.003480.</mixed-citation><mixed-citation xml:lang="en">Tremblay­Gravel M, Ichimura K, Picard K, et al. Intrinsic Atrial Myopathy Precedes Left Ventricular Dysfunction and Predicts Atrial Fibrillation in Lamin A/C Cardiomyopathy. Circ Genom Precis Med. 2023;16(1):e003480. doi:10.1161/CIRCGEN.121.003480.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Vaikhanskaya TG, Dubovik TA, Levdansky OD, et al. Atrial fibrillation in patients with dilated cardiomyopathy: prevalence, risk factors and prognostic significance. Russian Journal of Cardiology.2023;28(11):5544. (In Russ.) Вайханская Т.Г., Дубовик Т.А., Левданский О.Д., и др. Фибрилляция предсердий у пациентов с дилатационной кардиомиопатией: распространенность, факторы риска и прогностическая значимость. Российский кардиологический журнал. 2023;28(11):5544. doi:10.15829/1560-4071-2023-5544.</mixed-citation><mixed-citation xml:lang="en">Vaikhanskaya TG, Dubovik TA, Levdansky OD, et al. Atrial fibrillation in patients with dilated cardiomyopathy: prevalence, risk factors and prognostic significance. Russian Journal of Cardiology. 2023;28(11):5544. (In Russ.) doi:10.15829/1560­4071­2023­5544.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Berdibekov BSh, Bulaeva NI, Alexandrova SA, et al. Sudden cardiac death risk stratification in dilated cardiomyopathy: a state-of-the-art review. Russian Journal of Cardiology. 2025;30(6S):6114. (In Russ.) Бердибеков Б.Ш., Булаева Н.И., Александрова С.А., и др. Стратификация риска внезапной сердечной смерти при дилатационной кардиомиопатии: обзор современного состояния проблемы. Российский кардиологический журнал. 2025;30(6S):6114. doi:10.15829/1560-4071-2025-6114.</mixed-citation><mixed-citation xml:lang="en">Berdibekov BSh, Bulaeva NI, Alexandrova SA, et al. Sudden cardiac death risk stratification in dilated cardiomyopathy: a state­ofthe­art review. Russian Journal of Cardiology. 2025;30(6S):6114. (In Russ.) doi:10.15829/1560­4071­2025­6114.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kucher AN, Sleptcov AA, and M. S. Nazarenko MS. Pathogenetics of Cardiomyopathy/ Genetics. 2023;59(6):615-632. (In Russ.) Кучер А.Н., Слепцов А.А., Назаренко М.С. Патогенетика кардиомиопатий. Генетика. 2023;59(6):615–632. doi: 10.31857/S0016675823050107.</mixed-citation><mixed-citation xml:lang="en">Kucher AN, Sleptcov AA, Nazarenko MS. Pathogenetics of Cardiomyopathy. Genetics. 2023;59(6):615­32. (In Russ.) doi:10.31857/S0016675823050107.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
